scholarly journals Clinical Efficacy of Allergen-Specific Immunotherapy from Patient and Physician Perspectives

2019 ◽  
Vol 60 (5) ◽  
pp. 446 ◽  
Author(s):  
Yoo Seob Shin ◽  
Jae-Woo Jung ◽  
Jung-Won Park ◽  
Jeong-Hee Choi ◽  
Jae-Woo Kwon ◽  
...  
Immunotherapy ◽  
2013 ◽  
Vol 5 (3) ◽  
pp. 203-206 ◽  
Author(s):  
Mohamed H Shamji ◽  
Christian Ljørring ◽  
Peter A Würtzen

2016 ◽  
Vol 13 (4-5) ◽  
pp. 68-71
Author(s):  
E F Glushkova ◽  
O I Sidorovich

Background. To evaluate the effectiveness of one course of sublingual allergen-specific immunotherapy (sASIT) in adults with allergy to wormwood and goose-foot pollen. Materials and methods. 28 adults aged between 20 and 53 years old with various forms of respiratory allergy were included in the study. All of them received sASIT with Antipollin Mixed weeds. The effectiveness of treatment was assessed using a visual analogue scale of rhinoconjunctivitis symptoms and Asthma Control Questionnaire. Results. As a result of sASIT a 61,6% of rhinorrhea, a 61,6% of nasal congestion , a 71,43% of nasal itching, and 82% of eyes itching reduction was shown as well as asthma control was achieved in 83,3% of patients.


2016 ◽  
Vol 144 (5-6) ◽  
pp. 345-350 ◽  
Author(s):  
Zorica Zivkovic ◽  
Ivana Djuric-Filipovic ◽  
Snezana Zivanovic

In 1993 the European Academy of Allergy and Clinical Immunology was the first official organization to recognize that sublingual administration could be ?promising route? for allergic desensitization. A few years later, the World Health Organization recommended this therapy as ?a viable alternative to the injection route in adults.? The first meta-analysis showed sublingual allergen specific immunotherapy (SLIT) effectiveness for allergic rhinitis and another study showed SLIT can actually help prevent the development of asthma both in adults and in children. The main goal of this review article is to present insight into the most up-to-date understanding of the clinical efficacy and safety of immunotherapy in the treatment of pediatric patients with allergic rhinitis and asthma. A literature review was performed on PubMed from 1990 to 2015 using the terms ?asthma,? ?allergic rhinitis,? ?children,? ?allergen specific immune therapy.? Evaluating data from double-blind placebo-controlled randomized clinical trials (DB-PC-RCTs), the clinical efficacy (assessed as the reduction of symptom score and the need of rescue medicament) of SLIT for allergic rhinitis and allergic asthma, has been confirmed in various meta-analysis Outcomes such as rhinoconjunctivitis score and medication scores, combined scores, quality of life, days with severe symptoms, immunological endpoints, and safety parameters were all improved in the SLIT-tablet compared with placebo group. SLIT safety has been already proven in many DB-PC-RCTs and real-life settings. In accordance with all of the above mentioned, the goals for future trials and studies are the development of comprehensive guidelines for clinical practice on immunotherapy, embracing all the different potential participants. The importance of allergen immunotherapy is of special relevance in the pediatric age, when the plasticity and modulability of the immune system are maximal, and when preventative effects can be reasonably expected.


Sign in / Sign up

Export Citation Format

Share Document